PSMA PET/CT scan to assess Ra-223 treatment in advanced prostate cancer
Part of Cancer, Kidney & urinary clinical trials.
This trial studies whether a special whole-body scan (PSMA PET/CT) can help assess how well Ra-223 (a targeted treatment) may work in men with advanced prostate cancer that has spread to the bones. It may help doctors choose and plan Ra-223 treatment more effectively.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a man age 40 to 85
- You have metastatic castration-resistant prostate cancer (mCRPC) and meet criteria for Ra-223 due to symptomatic bone metastases (at least two bone spots) and no spread to internal organs
- You can sign the informed consent and have a life expectancy of more than 3 months
- Your general function is good enough for study procedures (ECOG 0 to 2)
- You can safely complete the PET/CT scan (no severe claustrophobia, you can stay still, you are alert, and your vital signs are stable)
- Your kidney and liver tests are safe for the scan and related procedures (kidney filtering not too low; no contrast allergy; liver enzymes not more than 3 times normal)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a special scan (PSMA PET/MRI) combined with a standard MRI can better detect prostate cancer. It is for men who have not had a biopsy yet and are suspected of having prostate cancer.
This study uses two different PSMA PET/CT tracers to see how well they detect cancer in patients with advanced prostate cancer that has spread or stopped responding to hormone therapy. The goal is to improve imaging for better treatment decisions.
This trial tests whether a special PET scan can predict how well a targeted radiation therapy (177Lu-PSMA-617) works for men with advanced prostate cancer that has stopped responding to hormone therapy. It aims to personalize treatment by checking the radiation dose before therapy starts.
This trial tests a new imaging approach (radium-based) for men with prostate cancer that has spread to the bones and is getting worse. It aims to see if this helps better target treatment and improve outcomes.
This study uses a special scan called PET/MR with a prostate-focused tracer to help doctors choose the best next treatment for prostate cancer. It may be most helpful if you are planning major treatment or if your cancer has come back after prior treatment.
This study uses a special type of scan called a PSMA PET to see how well different prostate cancer treatments are working. It is for people with advanced prostate cancer who are about to start or change systemic therapy.
Hear when a new Metastatic Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.